大肠癌治疗性生物标志物的病理学评价。

Q1 Medicine
Esther Baranov MD, Jonathan A. Nowak MD, PhD
{"title":"大肠癌治疗性生物标志物的病理学评价。","authors":"Esther Baranov MD, Jonathan A. Nowak MD, PhD","doi":"10.1016/j.path.2023.05.002","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":39485,"journal":{"name":"Surgical Pathology Clinics","volume":"16 4","pages":"Pages 635-650"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pathologic Evaluation of Therapeutic Biomarkers in Colorectal Adenocarcinoma\",\"authors\":\"Esther Baranov MD, Jonathan A. Nowak MD, PhD\",\"doi\":\"10.1016/j.path.2023.05.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":39485,\"journal\":{\"name\":\"Surgical Pathology Clinics\",\"volume\":\"16 4\",\"pages\":\"Pages 635-650\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Surgical Pathology Clinics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1875918123000429\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical Pathology Clinics","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1875918123000429","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

分子检测是结直肠癌病理评估的重要组成部分,可提供诊断、预后和预测性治疗信息。所有肿瘤都需要进行错配修复状态评估。晚期和转移性肿瘤还需要确定肿瘤突变负荷、KRAS、NRAS和BRAF突变状态、ERBB2扩增状态以及NTRK和RET基因重排状态,以指导治疗。通常需要多种检测,包括免疫组织化学、微卫星不稳定性检测、MLH1启动子甲基化和下一代测序。病理学家必须意识到这些要求,以便对组织进行最佳分类。结直肠癌癌症分子诊断的进展将继续推动结直肠癌癌症个性化治疗的改进。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pathologic Evaluation of Therapeutic Biomarkers in Colorectal Adenocarcinoma
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Surgical Pathology Clinics
Surgical Pathology Clinics Medicine-Surgery
CiteScore
4.40
自引率
0.00%
发文量
73
期刊介绍: This newest addition to the Clinics Series keeps you current on the information that is essential to every practicing surgical pathologist, from the latest techniques and approaches to detailed discussions on differential diagnosis. It devotes each and every issue exclusively to surgical pathology and its associated problems and is enhanced by abundant full-color images. Each issue focuses on a single topic-and is overseen by Guest Editors who are experts in their field-providing information of practical value on service while also offering material that increases understanding.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信